Ozempic, Wegovy and Mounjaro (GLP-1) Blood Test

OZEMPIC, WEGOVY AND MOUNJARO BLOOD TEST

Regular blood tests play a crucial role in the management and optimisation of Ozempic and Wegovy therapy, both of which are GLP-1 receptor agonists indicated for weight loss and glycaemic control in the UK. This is important and our clinical governance team advises you to pay attention to the side effects.

Monitoring key biomarkers, such as HbA1c levels, liver enzymes, kidney function, and lipid profiles, ensures that any underlying issues are identified and addressed promptly. Additionally, these routine blood tests can help your prescriber (and you!) determine the effectiveness of the medication, offering valuable insights into whether dosing adjustments or supplementary treatments are required.

From a technical standpoint, GLP-1 receptor agonists like Ozempic and Wegovy influence the release of insulin, slow gastric emptying, and modulate hunger signals, which in turn affect metabolic parameters. By consistently reviewing blood test results, you or your doctor can detect patterns or abnormalities that may indicate the onset of potential side effects such as pancreatitis or changes in thyroid function. Potential complications can be minimised, ensuring that the therapeutic benefits of the medication are realised without compromising your wellbeing.

You should insist that your provider maintains evidence-based care via blood diagnostics, adjust treatment strategies as needed, and enhance your results. Ultimately, ongoing blood monitoring not only helps ensure your safety but also optimises the long-term success of these powerful weight loss and type 2 diabetes management options.

34 BIOMARKERS